ETX — E-Therapeutics Share Price
Last trade - 00:00- £54.93m
- £23.53m
- £0.48m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.66 | ||
| Price to Tang. Book | 1.67 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 115.64 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -30.99% | ||
| Return on Equity | -27.23% | ||
| Operating Margin | -2155.58% | ||
Financial Summary
| Year End 31st Jan | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 0.04 | 0.46 | 0.32 | 0.48 | 0.47 | 0.5 | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
e-Therapeutics Plc is a drug discovery platform company. It is engaged in developing a computational approach to drug discovery, leveraging network biology to capture and interrogate human disease complexity. Its biology-led silico laboratory enables hypothesis generation, phenotypic screening and the identification and prioritization of novel therapeutic targets. It has developed a proprietary GalNAc-siRNA platform technology for specific silencing of gene expression in the liver. Its computational platform includes HepNet, a hepatocyte-specific, computational biology platform that enables identification of target genes to unlock differentiated therapeutic development at scale. Its GalOmic platform is its proprietary ribonucleic acid (RNA) Interference (RNAi) chemistry platform. In combination with HepNet, it offers end-to-end capabilities for rapid identification of novel disease-associated genes and drug candidate development of therapies with disease-modifying potential.
Directors
- Trevor Jones NEC (77)
- Ali Mortazavi CEO (50)
- Michael Bretherton CFO
- Stephanie Maley CHO
- Jonny Wray CTO
- Alan Whitmore CSO
- Laura Roca-alonso OTH
- Colin Stubberfield OTH
- Last Annual
- January 31st, 2023
- Last Interim
- January 31st, 2023
- Incorporated
- October 15th, 2001
- Public Since
- November 28th, 2007
- No. of Employees
- 38
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 584,335,487
- Address
- Floor 4, LONDON, W2 6BD
- Web
- https://www.etherapeutics.co.uk/
- Phone
- +44 2045518888
- Auditors
- Crowe U.K. LLP
Latest News for ETX
Upcoming Events for ETX
E-Therapeutics PLC Annual Shareholders Meeting
Half Year 2025 E-Therapeutics PLC Earnings Release
Similar to ETX
4Basebio
London Stock Exchange
Allergy Therapeutics
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
Batm Advanced Communications
London Stock Exchange
FAQ
As of Today at 19:08 UTC, shares in E-Therapeutics are trading at 9.40p. This share price information is delayed by 15 minutes.
Shares in E-Therapeutics last closed at 9.40p and the price had moved by -19.14% over the past 365 days. In terms of relative price strength the E-Therapeutics share price has underperformed the FTSE All Share Index by -23.24% over the past year.
The overall consensus recommendation for E-Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreE-Therapeutics does not currently pay a dividend.
E-Therapeutics does not currently pay a dividend.
E-Therapeutics does not currently pay a dividend.
To buy shares in E-Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 9.40p, shares in E-Therapeutics had a market capitalisation of £54.93m.
Here are the trading details for E-Therapeutics:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: ETX
Based on an overall assessment of its quality, value and momentum E-Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like E-Therapeutics. Over the past six months, its share price has underperformed the FTSE All Share Index by -26.62%.
As of the last closing price of 9.40p, shares in E-Therapeutics were trading -26.54% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The E-Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 9.40p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
E-Therapeutics' management team is headed by:
- Trevor Jones - NEC
- Ali Mortazavi - CEO
- Michael Bretherton - CFO
- Stephanie Maley - CHO
- Jonny Wray - CTO
- Alan Whitmore - CSO
- Laura Roca-alonso - OTH
- Colin Stubberfield - OTH